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Introduction
Microglia are tissue-resident macrophages that perform CNS-
specific functions (1). They derive from a unique lineage of eryth-
romyeloid precursors (EMPs) in the yolk sac and fetal liver (2). 
EMPs infiltrate the brain during early development, differentiate 
into microglia, and maintain their population by self-renewal (3). 
Microglia distribute themselves throughout the CNS (4) and con-
tinuously scan their surroundings (5). Microglia share many traits 
with other subsets of tissue-resident macrophages, including 
dependence on the CSF1 receptor (CSF1R) for differentiation and 
survival, a requirement for PU.1 as an essential lineage-determin-
ing transcription factor (LDTF), the ability to efficiently phagocy-
tose tissue debris, and the ability to quickly trigger an inflammato-
ry response following detection of pathogens or tissue damage (6). 
In addition to responding to injury and infection, microglia carry 
out functions that are specific to the CNS environment, includ-
ing secretion of neurotrophic factors and developmental refine-
ment of synaptic networks (7, 8). Upon activation, microglia can 
acquire a range of phenotypes that can either contribute to disease 
progression or ameliorate it (9). Although dysregulated microglia 
are implicated in the pathogenesis of several neurodegenerative 
and psychiatric conditions (10), mechanisms controlling develop-
mental, homeostatic, and pathogenic programs of microglia gene 
expression remain poorly understood.
Insights into the transcriptional regulation of cell type–specific 
functions can be obtained by analysis of transcriptional regula-
tory elements (11). Promoters provide the obligatory transcriptional 
start sites necessary for RNA synthesis and are often sites of signal-
dependent regulation (Figure 1). However, they are primarily occu-
pied by broadly expressed transcription factors (TFs) such as SP1 
and GABP, and by themselves are insufficient to confer the specific 
regulatory control necessary to generate cell type–specific programs 
of gene expression. This additional information is provided by distal 
regulatory elements called enhancers (12). Enhancers represent the 
most numerous binding sites for LDTFs and signal-dependent tran-
scription factors (SDTFs), and are major sites for the integration of 
internal and external signals. Enhancers exhibit distinctive patterns 
of modifications to adjacent histones that can be detected by ChIP 
sequencing (ChIP-Seq), and these patterns can be used to putative-
ly classify enhancers as inactive, primed, or active (13).
In vitro studies of elicited peritoneal macrophages provid-
ed the basis for a collaborative/hierarchical model of enhancer 
selection and activation involving interactions between LDTFs 
and SDTFs (14–16). According to this model, the initial steps of 
enhancer selection are driven by collaborative interactions of 
LDTFs and other “pioneer” factors that recognize factor-specific 
DNA sequences in closed chromatin and generate nucleosome-
free regions (17). The selection of enhancers is thought to be a 
collaborative process requiring interactions between multiple fac-
tors that recognize closely spaced arrangements of corresponding 
recognition motifs (18). Initial occupancy of enhancers by LDTFs 
and their collaborative partners can result in histone modifica-
tions associated with a primed state of activity. The transition 
from an inactive or primed state to an active enhancer can be 
induced by SDTFs (19, 20) (Figure 2) that are activated in response 
to stimuli through cell signaling pathways that often originate at 
cell surface receptors. These SDTFs mainly bind to enhancers 
previously established by LDTFs (15, 16, 21, 22). This process is 
frequently hierarchical such that SDTF binding is dependent on 
LDTF binding, whereas loss of the SDTF does not influence the 
binding of the LDTF (14, 21, 23). The observation that SDTFs are 
directed to a predetermined set of cell-specific enhancers at least 
partly explains how a broadly expressed TF can regulate specific 
transcriptional responses in different cell types. Importantly, the 
distinction between LDTFs and SDTFs is not always clear cut, as 
some TFs that regulate the ontogeny of a cell type can also serve 
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matures, microglia acquire a surveilling phenotype and express 
the TFs Jun, Fos, Mef2a, and Mafb, as well as a set of genes that are 
highly expressed in microglia such as the characteristic purinergic 
receptor P2RY12, the transmembrane protein TMEM119, and the 
chemokine receptor CX3CR1 (31–34), the expression of which is 
largely conserved in humans (35–37) and zebrafish (38).
Compared with monocytes and neutrophils, macrophage 
enhancers are enriched for a MAF binding motif with Maf and 
Mafb as the highest expressed corresponding TFs, raising the pos-
sibility that these TFs may act collaboratively with PU.1 to specify 
a general macrophage identity (39). In contrast, microglia enhanc-
ers, when compared with other tissue macrophages, were enriched 
for a MEF2 binding motif and exhibited high expression of the 
cognate TF Mef2c (39, 40). A comparison with peritoneal mac-
rophages showed that PU.1-bound enhancers in microglia were 
enriched for PU.1-IRF, HIC2, MEF2, and SMAD binding motifs, 
implicating these TFs as potential collaborative partners of PU.1. 
However, enrichment alone cannot establish whether these factors 
act as LDTFs in collaboration with PU.1 or merely cobind already-
established enhancers. To overcome this limitation, experiments 
exploiting natural genetic variation between two strains of mice 
were performed, in a manner analogous to a mutagenesis experi-
ment. These experiments showed that disruption of binding sites 
for STAT3, MAFB, SMAD3, and upstream TF-1 (USF1) affected 
nearby PU.1 binding specifically in microglia, and these may there-
fore function as microglia-specific collaborative factors (40).
Systematic analyses of human microglia gene expression 
from postmortem (36) and surgical tissues (37) indicate broad 
similarities with mice but also a number of significant differ-
ences, including genes implicated in neurodegenerative diseases. 
Further, age-related changes in gene expression differed signifi-
cantly between mice and humans (36). Both human and mouse 
microglia enhancers are enriched for motifs associated with PU.1, 
IRF, RUNX, MEF2, C/EBP, AP-1, SMAD, and MAF (37), indicat-
ing a conserved set of microglia LDTFs. However, Sall2, Sall3, and 
Smad1 were expressed much more highly in mice, while class II 
MHC transactivator (CIITA), PPARG, EGR3, and RUNX2 were 
preferentially expressed in human microglia. These findings sug-
gest that the differences between mouse and human microglia 
gene expression are mainly driven by species-specific organiza-
tion of regulatory elements, but some differences also result from 
differential expression of TFs.
The importance of the brain environment in maintaining 
microglia identity is suggested by the rapid and extensive changes 
in gene expression that occurred when they were transferred from 
the brain to an in vitro environment (32, 37, 40, 41). Substantial 
subsets of genes associated with risk alleles for neurodegenerative 
or behavioral diseases exhibited environment-dependent expres-
sion (37). Genes that were downregulated in vitro were highly cor-
related with genes that are upregulated in primitive macrophages 
following their migration into the fetal brain (28, 37). These 
changes in gene expression are associated with downregulation 
of numerous putative microglia LDTFs, such as Sall1 and corre-
sponding alterations in enhancer landscapes. Collectively, these 
findings provide evidence for an important role of brain-derived 
signals in controlling a conserved network of signal-dependent 
and lineage-determining TFs in mouse and human microglia.
as mediators for particular environmental stimuli. In this Review, 
we examine microglia development and function in the context of 
this general model, with a focus on roles of the major LDTFs and 
SDTFs that are expressed in microglia.
Transcriptional control of microglia identity
Microglia derive from a population of EMPs in the extraembryonic 
yolk sac during the process of primitive hematopoiesis (2, 24). In 
mice, EMPs exclusively express the TF runt-related TF-1 (RUNX1) 
between E6.5 and E8.0. Microgliogenesis is crucially dependent 
on the TFs PU.1 and interferon regulatory factor-8 (IRF8), but not 
on the TFs inhibitor of DNA binding-2 (ID2); basic leucine zipper 
TF, ATF-like-3 (BATF3); Krüppel-like factor-4 (KLF4); and MyB 
(25, 26). In the yolk sac EMPs differentiate into premacrophages 
(pMacs) that express a core macrophage program that includes the 
receptors CX3CR1 and CSF1R, as well as the TFs Maf, Batf3, Pparg, 
Irf8, and zinc finger E-box binding homeobox-2 (Zeb2) (27), a pro-
gram that persists when these precursors infiltrate various organs 
to establish resident macrophage populations. Microglia develop-
ment has been proposed to progress in three developmental stages 
(28): early microglia (until E14), premicroglia (from E14 to the first 
weeks after birth), and adult microglia (from a few weeks after birth 
onward). Early microglia, like EMPs, express genes associated with 
cell cycle signaling pathways and the TF E2f6 and DNA methyl-
transferase-1 (Dnmt1), which may help them populate the brain. The 
genes expressed by premicroglia, including the TFs early growth 
response-1 (Egr1) and spalt-like TF-1 (Sall1), are associated with 
neural maturation and synaptic pruning (29, 30). Later, as the brain 
Figure 1. Enhancers and promoters interact to confer cell type–specific 
expression and response profiles. Promoters are primarily occupied 
by general sequence-specific transcription factors (TFs), but are also 
important sites of action of lineage-determining TFs (LDTFs) and signal-
dependent TFs (SDTFs). Enhancers are primarily selected by LDTFs and are 
usually the most numerous binding sites for SDTFs. External and internal 
signals converge on SDTFs to regulate enhancer and promoter function.
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microglia are more proinflammatory and phagocytic, and show 
downregulation of the microglia-specific gene expression signa-
ture (29). This altered microglia phenotype has detrimental con-
sequences for neurogenesis and tissue homeostasis. Taken togeth-
er, these studies suggest that SALL1 inhibits a reactive microglia 
phenotype, and promotes a physiological surveilling phenotype.
MAFB. MAFB is a member of the large MAF subfamily of TFs 
that binds to the MAF recognition element and forms heterodimers 
with cMAF, Jun, and Fos. In macrophages, MAFB promotes an anti-
inflammatory phenotype, and its deletion exacerbates inflamma-
tory and pathological conditions (47, 48). In microglia, expression 
of MAFB increases during microglia development, and its deletion 
disrupts gene expression in adult microglia more severely than in 
premature microglia (28). Motif mutation analysis suggests that 
MAFB functions as an LDTF in collaboration with PU.1 (40). In 
microglia, MAFB regulates the expression of immune and viral 
genes (28), and its expression is downregulated in the SOD1 mouse 
model of amyotrophic lateral sclerosis (49). In primary microglia, 
MAFB regulates cell division by dampening the response to gran-
ulocyte-macrophage CSF (50). These findings suggest that MAFB 
helps to maintain a healthy adult microglia phenotype by inhibiting 
inflammatory and proliferative responses.
Transcriptional control of disease phenotypes
In disease conditions, microglia can adopt various phenotypes that 
exert beneficial and deleterious effects, including tissue support, 
excessive pruning of synapses, induction of neuropathic pain, and 
exacerbation of neurodegeneration (51). New studies are begin-
LDTFs that establish physiological microglia
Many of the TFs implicated in defining the microglia cell type 
during development have been shown to play roles in maintain-
ing microglia in a ramified and surveilling state that is character-
istic of healthy brain tissue. We discuss three important and well-
described transcriptional regulators in more detail below.
PU.1. PU.1 is a well-characterized LDTF that appears to serve 
as a master regulator of the myeloid lineage (42). PU.1 is essential 
for establishing macrophage lineages, drives microgliogenesis, 
and is a major factor in selecting the microglia enhancer land-
scape. PU.1-deficient mice exhibit multiple hematopoietic abnor-
malities and a pronounced depletion of B cell and macrophage 
populations (43). PU.1 deficiency also ablates microglia in mice 
(26) and zebrafish (44). Moreover, PU.1 binds to most enhancers 
in mouse (40) and human microglia (37), highlighting its central 
role in establishing the microglia enhancer landscape.
SALL1. SALL1 is a zinc finger transcriptional repressor that 
belongs to the SALL-like family of TFs that function in tissue mor-
phogenesis (45). SALL1 regulates cortical neurogenesis and lami-
nar fate specification in mice (46). Mutations in SALL1 are asso-
ciated with Townes-Brocks syndrome, an autosomal dominant 
developmental disorder in which roughly 10% of patients exhibit 
neural or behavioral abnormalities (46). Human and mouse 
microglia uniquely and highly express SALL1 as compared with 
other macrophage populations, suggesting that it functions as an 
LDTF (34, 35, 37). Sall1-deficient animals have normal microglia 
colonization in the brain, but the microglia exhibit an abnormal 
ameboid morphology (30). Moreover, in the absence of Sall1, 
Figure 2. Different classes of transcription factors 
interact and regulate cellular identity. The top of 
the figure illustrates the initial steps of enhancer 
selection in closed chromatin consisting of regularly 
positioned nucleosomes. Green and blue shading 
represents closely spaced binding sites for LDTFs. 
Below, collaborative interactions between LDTFs 
generate primed enhancers, characterized by a 
nucleosome-free region and monomethylated H3K4 
(H3K4me1). At the bottom of the figure, active 
SDTFs localize to primed enhancers, resulting in 
recruitment of coactivators and RNA polymerase II 
and generation of enhancer RNAs (eRNAs).
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Huntington’s disease (HD) (53). Multiple studies demonstrated 
increased microglial activation in HD patients, but it remained 
an open question whether this resulted from the action of mutat-
ed HTT (mHTT) in the microglia or represented the response 
of microglia to mHTT-induced changes in neurons. This was 
addressed by the expressing of mHTT in BV2 cells, resulting in 
increased expression of the SDTF NF-κB1 and the proinflam-
matory cytokines IL-6 and TNF, as well as increased expression 
and binding of the macrophage LDTFs PU.1 and C/EBP. Neurons 
that were cocultured with LPS-stimulated microglia expressing 
mHTT had increased apoptosis compared with neurons cocul-
tured with LPS-stimulated WT microglia.
SDTFs that mediate inflammation
As the resident macrophages of the CNS, microglia are the first 
to respond to inflammatory insults in the brain, which they do by 
expressing a wide array of cytokines, chemokines, nitric oxide (NO), 
and various reactive oxygen species (ROS). Several transcriptional 
families have been identified whose members regulate the expres-
sion of proinflammatory mediators in macrophages and microglia.
NF-κB family. Members of the NF-κB family are pleiotropic regu-
lators that play key roles in apoptosis and inflammation (54). NF-κB1 
(p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB, and c-Rel form 
ning to shed light on how these phenotypes are transcriptionally 
regulated (Figure 3). The collaborative/hierarchical model sug-
gests that, in disease, a unique combination of pathological and 
inflammatory factors activates SDTFs that regulate the expres-
sion of specific microglia response programs. A major obstacle 
to understanding the relationships among the different classes 
of TFs is that the environmental factors and pathological signals 
are complex and interact on multiple levels. The observation that 
culturing microglia so that they no longer receive brain-derived 
signals results in dramatic changes to their enhancer landscape 
(32, 37, 40) calls into question the extent to which findings about 
SDTFs obtained in vitro are translatable to microglia in vivo. Fur-
thermore, the frequently used immortalized murine microglia cell 
line, BV2, only partially recapitulates the response to a simple LPS 
stimulus observed in primary microglia (52). Given these differ-
ences, findings regarding the roles of SDTFs from in vitro studies 
should be interpreted with caution until they can be confirmed in 
in vivo conditions. Nevertheless, an increasing number of studies 
have identified transcriptional regulators of microglia activation 
and microglia phenotypes in pathological conditions.
The dynamic interaction between LDTFs and SDTFs in 
human disease is illustrated by the response of microglia to the 
mutant form of the huntingtin protein (HTT) responsible for 
Figure 3. Transcription factors that regulate different microglia phenotypes. Microglia ontogeny is crucially dependent on LDTFs such as PU.1, MAFB, and 
SALL1 that are essential for the development of the ramified phenotype depicted in the center. Microglia are diverse cells that acquire different functional 
phenotypes in response to the environment in which they reside. Several transcriptional regulators have been identified that regulate different microglia 
phenotypes. For example, proinflammatory microglia are regulated by IRF7, RelA, STAT1/3, and FosB. Microglia that mediate neuropathic pain are induced 
by expression of Irf1, Irf5, and Irf8 in microglia. Microglia that contribute to HIV-associated neurodegeneration are characterized by an induction of p53. 
Figure adapted with permission from Nature Reviews Neurology (128).
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mutants showed a complete absence of microglia (69). IRF8 has also 
been shown to regulate microglia motility (70).
In spinal cord microglia, IRF8, in conjunction with IRF1 
and IRF5, contributes to the induction of neuropathic pain after 
peripheral nerve injury (PNI) (71–74). IRF8 expression is markedly 
upregulated by PNI, which results in hypersensitivity to pain (71). 
IRF8 is upstream of IRF5, and Irf5-deficient mice exhibited sub-
stantial resistance to neuropathic pain (74). In microglia, IRF8 is 
also upstream of IRF1 and thereby regulates IL-1β expression after 
PNI (73). Collectively, these studies indicate that IRF8 is both a 
key regulator of microglia identity and a modulator of a reactive 
microglia phenotype associated with neuropathic pain.
IRF7 in microglia has been shown to promote both an anti-
inflammatory phenotype (75) and a proinflammatory phenotype 
(76). Downregulation of IRF7 by long-term exposure to TGF-β1 
or inhibition of IRF7 impairs the ability of microglia to acquire an 
antiinflammatory phenotype (75), while IFN-β–mediated acti-
vation of IRF7 restores the antiinflammatory phenotype. In spi-
nal cord injury, microglia overexpressing IRF7 have decreased 
proinflammatory activity (75). In contrast, IRF7 promotes LPS-
induced inflammation via phosphorylation of STAT1 (76). Recon-
ciliation of these two opposing observations concerning a single 
TF deserves further attention.
p53 tumor suppressor. p53 is a well-studied tumor suppressor 
gene that functions as a complex integrator of signals that regulate 
DNA damage repair, cell cycle progression, and apoptosis (77). The 
expression and activity of p53 increases in microglia in response to 
cellular stress, DNA damage, and oxidative stress (78–80). In post-
mortem brain tissues from patients with HIV-associated dementia 
(HAD) elevated levels of p53 were particularly prominent in the 
microglia (78, 81). HIV-infected p53-deficient neuron/microglia 
cocultures showed increased neuronal survival compared with WT 
(78). Microglial p53 activation is detrimental to neuronal synapses 
during inflammation (82). P53–/– microglia had lower expression of 
proinflammatory genes and demonstrated increased phagocytosis 
and expression of tissue support genes in response to IFN-γ (81). 
p53 may act to downregulate the antiinflammatory transcription 
factor cMAF through a transcriptional circuit involving TWIST2 
and miR-155 (83). Collectively these studies suggest that p53 regu-
lates microglia activity and induces a more reactive inflammatory 
profile with decreased tissue-supportive functions and phagocytic 
activity in HAD that might also play a more generic role in regulat-
ing microglia in disease.
STAT family. STAT TFs are pleiotropically expressed and 
mediate diverse functions such as proliferation, apoptosis, and 
differentiation in response to cytokines (63). STAT proteins form 
both homo- and heterodimers and become activated when phos-
phorylated STAT dimers translocate to the nucleus and bind to 
genomic elements. The binding pattern of STAT TFs is largely 
cell type–specific, and individual STAT members often bind in 
the proximity of cell type–specific TFs (84). Aberrant activation 
of JAK/STAT signaling in innate immune cells is associated with 
both multiple sclerosis (MS) and Alzheimer’s disease (AD) (85).
In mice, alterations in the STAT3 binding site affect near-
by PU.1 binding in microglia, suggesting that STAT3 functions 
as an LDTF (40). STAT1 and STAT3 also appear to function as 
SDTFs that regulate LPS-induced activation (86). In primary 
homodimers and heterodimers. Without stimulation, NF-κB is 
sequestered in the cytoplasm. Once activated, it translocates to the 
nucleus, where it binds to NF-κB binding sites exposed in open chro-
matin regions and induces the expression of target genes (55). Many 
studies have examined the role of NF-κB in brain aging and neuro-
degenerative conditions (54), but, since expression of NF-κB is not 
limited to microglia, most of these studies have focused on its role in 
other cell types or its generic expression in the brain.
In microglia, NF-κB is activated by signal transduction path-
ways responding to the presence of ROS (56), saturated fatty 
acids (57), α-synuclein (58, 59), and amyloid-β (60). The induced 
response can be either protective or deleterious depending on the 
context of the stimulation (61). A small number of studies have 
experimentally assessed the functional role of NF-κB in microg-
lia. Bacterial LPS is a TLR4 ligand that induces a strong immune 
response mediated by several TFs, including the NF-κB1/RelA 
complex. A single intraperitoneal injection of LPS has long-term 
consequences in microglia and results in blunted expression of pro-
inflammatory cytokines upon LPS restimulation; this attenuation is 
mediated in part by RelB (62). These observations exemplify how 
different members of the same NF-κB family can play antagonistic 
roles in inflammation and mediate changes in the microglia pheno-
type, and highlight the need for a more thorough understanding of 
how NF-κB family members regulate microglia phenotypes.
Activator protein-1 family. The activator protein-1 (AP-1) fam-
ily of TFs is involved in numerous processes including cell growth, 
differentiation, apoptosis, and immune activation (63). This fam-
ily consists of Jun, Fos, activating TF (ATF), and Jun dimerization 
protein (JDP) subfamilies, and its members can form both homo- 
and heterodimers. In macrophages, AP-1 members have been 
described to function as both LDTFs (15) and SDTFs (64). Simi-
larly, in microglia, Jun and Fos are upregulated during microglia 
development, suggesting that they play roles as LDTFs that regu-
late microglia identity (28). However, FosB has been suggested to 
function as an SDTF that regulates excitotoxic microglia activation 
(65). Constitutive Fosb-knockout mice were relatively resistant to 
kainate-induced excitotoxicity, with fewer ameboid microglia, 
and less expression of the proinflammatory cytokines IL-6 and 
TNF compared with their WT counterparts. Since FosB expression 
is similar between hippocampal neurons and microglia, it is cur-
rently unclear whether FosB ablation directly affects microglia, 
neurons, or both. More research into the role of AP-1 members in 
microglia is needed for a better understanding of how these fac-
tors regulate both microglia identity and pathological phenotypes.
Interferon regulatory factors. The interferon regulatory fac-
tor (IRF) family consists of nine members that bind to genomic 
loci known as interferon-sensitive response elements. IRF3, IRF5, 
and IRF7 mediate type I interferon responses induced by various 
TLR ligands (66), while IRF1 is essential for the type II interferon 
response (63). In microglia, IRF8 is a key regulator that appears to 
function as both an LDTF and an SDTF. IRF8 was recently identified 
as an essential regulator of tissue macrophage maturation, including 
microglia (27, 67). Irf8 deletion substantially reduces microglia num-
bers in mice (26). Microglia-specific disruption of Irf8 resulted in a 
pronounced reduction in microglia ramification and surface area as 
well as altered expression of several cell surface markers, indicating 
increased microglia immune activation (68). In zebra fish, Irf8-null 
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mouse microglia, changes in the binding of STAT1, STAT3, and 
STAT5 in response to LPS were assessed, and a group of STAT-
regulated inflammatory genes was identified including the his-
tone 3 lysine-27 (H3K27) demethylase JMJD3. The expression of 
these putative target genes was only affected if both STAT1 and 
STAT3 were inhibited simultaneously using siRNA in BV2 cells, 
suggesting a functional redundancy between these two factors. 
Knockdown of both STAT1 and STAT3 inhibited the expression of 
JMJD3 and other inflammatory genes. This evidence suggests that 
STAT1/STAT3 signaling regulates expression of inflammatory 
mediators in microglia, possibly via JMJD3.
Antiinflammatory and tissue-supportive 
mediators
Excessive inflammation in the CNS is detrimental for neuronal 
health (87). Not surprisingly, several transcriptional mechanisms 
limit the inflammatory responses of microglia and induce neuro-
protective behavior.
MSX family. The Msh-like homeobox (MSX) genes are part 
of the homeobox family and are implicated in brain develop-
ment and neurogenesis (88). In microglia, MSX3 is normally lowly 
expressed but upregulated during experimental autoimmune 
encephalomyelitis (EAE) in mice (89). Transplantation of MSX3-
overexpressing microglia to EAE mice resulted in milder EAE 
clinical scores, increased remyelination, and decreased inflamma-
tion. ChIP analysis indicated that MSX3 bound at the promoters of 
Pparg, Stat6, and Jak3, suggesting that it might exert its effect by 
regulating these genes. This study suggests that MSX3 might play 
a role in maintaining a tissue-supportive phenotype in microglia.
NR4A2. Nuclear receptor subfamily 4, group A, member 2 
(NR4A2, also known as NURR1) plays an essential role in the 
generation and maintenance of dopaminergic neurons in the 
brain (90). Mutations in NR4A2 are associated with familial Par-
kinson’s disease (PD) (91). In microglia, NR4A2 inhibits LPS-
induced expression of proinflammatory cytokines (92). Reduced 
NR4A2 expression results in exaggerated inflammatory responses 
in microglia and increases dopaminergic neuron death. NR4A2 
exerts an antiinflammatory effect by binding to RelA on inflam-
matory gene promoters and recruits the CoREST corepressor 
complex, which clears RelA and represses transcription. Addi-
tionally, pharmacological activation of NR4A2 in BV2 cells blocks 
inflammatory gene expression by inhibiting RelA (93), suggest-
ing that NR4A2 is an antiinflammatory regulator that counteracts 
RelA-based inflammation in microglia.
Estrogen receptors. Estrogen receptor-α (ERα) and ERβ are a sub-
class of the nuclear receptor superfamily that function as estrogen-
dependent TFs. Estrogens exert neuroprotective actions by signal-
ing through ERs that are widely distributed in the male and female 
brain (94). Estradiol is not only a reproductive hormone but also a 
brain-derived neuroprotective factor in both males and females that 
enables ERs to coordinate multiple signaling mechanisms that pro-
tect the brain from neurodegenerative diseases. In microglia, estro-
gen signaling was also shown to exert antiinflammatory effects (95). 
Androstenediol (or 5-androsten-3β,17β-diol) is an estrogenic steroid 
produced in the brain that binds to ERβ. Androstenediol activa-
tion of ERβ suppresses the inflammatory responses of microglia 
by recruitment of C-terminal binding protein (CtBP) corepressor 
complexes to AP-1–dependent promoters (96). Reduction of andro-
stenediol or ERβ expression results in exaggerated LPS responses, 
and administration of androstenediol in vivo prevents EAE. These 
findings provide evidence for an ERβ signaling pathway that con-
trols inflammatory responses in microglia.
Nuclear respiratory factor 2. Nuclear respiratory factor 2 (NRF2, 
also referred to as nuclear factor 2 erythroid 2 like 2 [NFE2L2]) 
regulates an antioxidant response to the oxidative damage that 
is characteristic of many neurodegenerative conditions (97). In 
macrophages, NRF2 expression represses inflammation not only 
by regulating the antioxidative defense (98), but also by directly 
inhibiting the recruitment of RNA polymerase II to Il6 and Tnf 
(99). Many studies suggest that NRF2 activation is involved in 
neuroprotection (97) by regulating antioxidative proteins such 
as heme oxygenase-1 (HO-1). In microglia, NRF2 has been dem-
onstrated to counteract inflammation and neurodegeneration in 
the tau pathology model for AD (100), the MPTP model for PD 
(101), hematoma (102), and LPS-induced inflammation (103). 
Stressed neurons signal microglia through fractalkine to induce 
the NRF2-mediated antioxidative response (100). These findings 
were corroborated in human AD brain tissues, suggesting that 
this mechanism might be an adaptive tissue-restorative response 
to pathological conditions. Besides regulating the antioxidative 
response, NRF2 has also been implicated in regulation of phago-
cytic clearance, a process that is essential for the uptake of blood 
cells in hematoma, via upregulation of CD36 (102). Collectively, 
these results indicate that NRF2 dampens inflammation through 
mediating the antioxidative response and facilitating phagocy-
tosis, thereby positioning it as a crucial regulator of a microglia 
tissue-restorative phenotype.
SDTFs that regulate cholesterol and lipid 
metabolism
Lipids and cholesterol derivatives are essential for the CNS, where 
they function as key components of myelin sheets, synapses, den-
drites, and intercellular signaling molecules (104, 105). Defects 
in cholesterol metabolism are clearly described in neurodegen-
erative diseases (106). The PPAR and liver X receptor/retinoid X 
receptor (LXR/RXR) families play key roles at the crossroads of 
lipid and cholesterol metabolism with immune responses in tissue 
macrophages (107). In microglia, much less is known about these 
factors since, to date, no studies have experimentally targeted 
members of the LXR/RXR or the PPAR family to microglia in vivo.
PPARs. The PPAR family of nuclear receptor TFs consists of 
three members: PPARα, PPARδ, and PPARγ. PPARs function as lipid 
sensors and are involved in fatty acid metabolism (108). In adipose-
resident macrophages, members of the PPAR family are implicated 
in suppressing fatty acid–induced inflammation associated with 
obesity and metabolic syndrome by increasing fatty acid oxidation 
(109). PPARγ is a central switch that inhibits the expression of pro-
inflammatory mediators (110) and induces a wound healing pheno-
type (111, 112). However, the role of PPARs in microglia and neuro-
inflammation is still poorly understood. A rapidly growing number 
of studies have investigated the role of PPARγ agonists in neuro-
degenerative conditions such as AD, PD, HD, and amyotrophic 
lateral sclerosis, but these findings have not conclusively shown a 
protective effect (113). However, in AD mice, a PPARγ agonist did 
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show beneficial effects by counteracting neurodegeneration, lower-
ing amyloid-β deposits, and inhibiting neuroinflammation (114). It 
has been suggested that the beneficial effects of PPARγ agonist are 
produced by inhibition of the proinflammatory activity of microglia 
and promotion of their phagocytic activity (115–117).
LXRs and RXRs. Liver X receptors (LXRs) and retinoid X 
receptors (RXRs) are nonsteroid nuclear receptors that play key 
roles in cholesterol homeostasis and inflammation (118, 119). The 
LXR isoforms LXRα and LXRβ can form dimers with any of the 
three RXR isoforms (RXRα, RXRβ, and RXRγ) and are activated 
in the presence of cholesterol derivatives such as oxysterols. In 
macrophages, the majority of LXR binding sites are found near 
PU.1-bound primed enhancers (15). LXRs have antiinflamma-
tory effects and modify macrophage phagocytic capability (120). 
Age-related neurodegenerative conditions have been linked to 
the disruption of cholesterol metabolism and LXR signaling (118). 
Likewise, LXR agonists have been shown to produce cognitive 
improvement in AD mouse models (121–123), but the mechanisms 
are not well understood. It has been suggested that the protective 
effects of LXR agonists are achieved by promotion of an increase 
in phagocytosis of amyloid-β by microglia (117), by inhibition of 
microglia nitric oxide synthetase (NOS) activity (124), or by atten-
uation of the microglia inflammatory response (125).
Conclusions and future perspectives
Many transcriptional regulators that mediate microglia in health 
and disease have been identified, but much remains unknown 
about their functional consequences, how they guide microglia 
phenotypic diversity, the effects of natural genetic variation, and 
their responses to specific signals in the local microenvironment.
One challenge is that many studies are purely descriptive or 
are performed on cultured microglia. The recent development 
of effective and inducible drivers of Cre-recombinase such as 
Cx3cr1-CreER (126) and Sall1-CreER (29) enables microglia- 
targeted knockout and overexpression of genes of interest. These 
tools could not only provide stronger and more detailed experi-
mental evidence but also give qualitatively new insights into the 
functional roles of TFs in regulating microglia in vivo.
A further challenge is to untangle the interrelationships 
between transcriptional regulators and the microglia enhancer 
landscape, which is required to understand the molecular mech-
anisms underlying their functional roles in microglia. With the 
increasing adoption of high-throughput technologies, it is now 
possible to map the binding patterns of different TFs in the con-
text of the enhancer landscape. Additionally, new techniques that 
unravel the 3D structure of chromatin, such as Hi-C, can be used 
to determine enhancer-promoter interactions, and help to address 
whether particular TFs regulate specific classes of enhancers.
Naturally occurring variation in noncoding regions of the 
genome can have modulatory effects on gene regulation or 
enhancer formation and could have considerable importance for 
understanding the involvement of such genetic variation in the 
roles of microglia in neurodegenerative diseases. Relatively large 
numbers of human microglia samples are necessary to determine 
whether disease-associated SNPs act on microglia expression 
and/or enhancer profiles. Therefore, the effect of natural genet-
ic variation on microglia expression and enhancer landscapes 
remains largely unexplored.
Another major aim for future research will be to identify 
the specific factors of the local CNS microenvironment, such as 
TGF-β or amyloid-β, that either help to maintain microglial physi-
ological identity or are responsible for disease-specific responses. 
Additionally, further identification of the TFs through which these 
signals are transduced to produce the microglia-specific patterns 
of gene expression remains an ongoing subject of investigation.
Microglia can exhibit a diverse range of phenotypes in response 
to their surroundings, but these phenotypes are much more com-
plex than the simple M1/M2 dichotomy (127) originally proposed 
for macrophages. Nor are these phenotypic states easily classi-
fied on a one-disease/one-phenotype basis. The proper frame-
work for cataloging microglia diversity across pathological condi-
tions, brain regions, local microenvironment, and developmental 
stages remains elusive. New technologies such as single-cell RNA 
sequencing and mass cytometry should facilitate a framework for 
microglia phenotype classification.
Finally, the degree to which findings about transcriptional 
regulation in mice and zebrafish translate to humans is critical for 
insight into the pathophysiology of neurodegenerative and neuro-
psychiatric diseases and is still largely unaddressed. Further stud-
ies of human microglia are essential to identify the strengths and 
weaknesses of animal and cell culture models.
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